![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RIPK2 |
Gene summary for RIPK2 |
![]() |
Gene information | Species | Human | Gene symbol | RIPK2 | Gene ID | 8767 |
Gene name | receptor interacting serine/threonine kinase 2 | |
Gene Alias | CARD3 | |
Cytomap | 8q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A0S2Z4Z8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8767 | RIPK2 | AEH-subject1 | Human | Endometrium | AEH | 3.62e-13 | 4.45e-01 | -0.3059 |
8767 | RIPK2 | AEH-subject2 | Human | Endometrium | AEH | 3.78e-04 | 2.52e-01 | -0.2525 |
8767 | RIPK2 | AEH-subject3 | Human | Endometrium | AEH | 1.08e-05 | 3.25e-01 | -0.2576 |
8767 | RIPK2 | AEH-subject4 | Human | Endometrium | AEH | 1.34e-15 | 5.29e-01 | -0.2657 |
8767 | RIPK2 | AEH-subject5 | Human | Endometrium | AEH | 5.58e-32 | 8.62e-01 | -0.2953 |
8767 | RIPK2 | EEC-subject1 | Human | Endometrium | EEC | 3.71e-15 | 5.25e-01 | -0.2682 |
8767 | RIPK2 | EEC-subject2 | Human | Endometrium | EEC | 1.64e-03 | 2.63e-01 | -0.2607 |
8767 | RIPK2 | EEC-subject4 | Human | Endometrium | EEC | 2.15e-07 | 3.41e-01 | -0.2571 |
8767 | RIPK2 | EEC-subject5 | Human | Endometrium | EEC | 9.07e-06 | 3.00e-01 | -0.249 |
8767 | RIPK2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.10e-06 | 2.65e-01 | -0.1869 |
8767 | RIPK2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.56e-07 | 2.43e-01 | -0.1875 |
8767 | RIPK2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.63e-05 | 1.82e-01 | -0.1883 |
8767 | RIPK2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.30e-07 | 3.24e-01 | -0.1934 |
8767 | RIPK2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.86e-10 | 2.06e-01 | -0.1917 |
8767 | RIPK2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.05e-07 | 1.70e-01 | -0.1916 |
8767 | RIPK2 | LZE4T | Human | Esophagus | ESCC | 6.14e-07 | 2.22e-01 | 0.0811 |
8767 | RIPK2 | LZE8T | Human | Esophagus | ESCC | 6.27e-04 | 1.66e-01 | 0.067 |
8767 | RIPK2 | LZE24T | Human | Esophagus | ESCC | 7.80e-06 | 7.19e-02 | 0.0596 |
8767 | RIPK2 | LZE6T | Human | Esophagus | ESCC | 1.29e-03 | 9.50e-02 | 0.0845 |
8767 | RIPK2 | P2T-E | Human | Esophagus | ESCC | 1.98e-33 | 7.92e-01 | 0.1177 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003313511 | Oral cavity | EOLP | regulation of peptidyl-serine phosphorylation | 33/2218 | 144/18723 | 1.33e-04 | 1.46e-03 | 33 |
GO:000223724 | Oral cavity | EOLP | response to molecule of bacterial origin | 67/2218 | 363/18723 | 1.42e-04 | 1.53e-03 | 67 |
GO:0043370 | Oral cavity | EOLP | regulation of CD4-positive, alpha-beta T cell differentiation | 16/2218 | 51/18723 | 1.75e-04 | 1.80e-03 | 16 |
GO:00455803 | Oral cavity | EOLP | regulation of T cell differentiation | 33/2218 | 146/18723 | 1.75e-04 | 1.81e-03 | 33 |
GO:00508514 | Oral cavity | EOLP | antigen receptor-mediated signaling pathway | 48/2218 | 240/18723 | 1.79e-04 | 1.84e-03 | 48 |
GO:003109824 | Oral cavity | EOLP | stress-activated protein kinase signaling cascade | 49/2218 | 247/18723 | 1.89e-04 | 1.94e-03 | 49 |
GO:0032607 | Oral cavity | EOLP | interferon-alpha production | 11/2218 | 28/18723 | 1.96e-04 | 2.00e-03 | 11 |
GO:0032647 | Oral cavity | EOLP | regulation of interferon-alpha production | 11/2218 | 28/18723 | 1.96e-04 | 2.00e-03 | 11 |
GO:00704318 | Oral cavity | EOLP | nucleotide-binding oligomerization domain containing 2 signaling pathway | 8/2218 | 16/18723 | 2.04e-04 | 2.05e-03 | 8 |
GO:003139821 | Oral cavity | EOLP | positive regulation of protein ubiquitination | 28/2218 | 119/18723 | 2.61e-04 | 2.53e-03 | 28 |
GO:004663311 | Oral cavity | EOLP | alpha-beta T cell proliferation | 13/2218 | 38/18723 | 2.68e-04 | 2.58e-03 | 13 |
GO:003248121 | Oral cavity | EOLP | positive regulation of type I interferon production | 17/2218 | 58/18723 | 2.78e-04 | 2.67e-03 | 17 |
GO:003134912 | Oral cavity | EOLP | positive regulation of defense response | 53/2218 | 278/18723 | 3.00e-04 | 2.81e-03 | 53 |
GO:005140324 | Oral cavity | EOLP | stress-activated MAPK cascade | 47/2218 | 239/18723 | 3.11e-04 | 2.91e-03 | 47 |
GO:190210713 | Oral cavity | EOLP | positive regulation of leukocyte differentiation | 34/2218 | 157/18723 | 3.32e-04 | 3.08e-03 | 34 |
GO:190370813 | Oral cavity | EOLP | positive regulation of hemopoiesis | 34/2218 | 157/18723 | 3.32e-04 | 3.08e-03 | 34 |
GO:00028193 | Oral cavity | EOLP | regulation of adaptive immune response | 38/2218 | 183/18723 | 3.75e-04 | 3.40e-03 | 38 |
GO:004212910 | Oral cavity | EOLP | regulation of T cell proliferation | 36/2218 | 171/18723 | 4.01e-04 | 3.58e-03 | 36 |
GO:0046638 | Oral cavity | EOLP | positive regulation of alpha-beta T cell differentiation | 15/2218 | 50/18723 | 4.75e-04 | 4.16e-03 | 15 |
GO:0042093 | Oral cavity | EOLP | T-helper cell differentiation | 18/2218 | 66/18723 | 4.94e-04 | 4.31e-03 | 18 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa0472216 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa0472217 | Endometrium | AEH | Neurotrophin signaling pathway | 31/1197 | 119/8465 | 4.07e-04 | 3.07e-03 | 2.25e-03 | 31 |
hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0472222 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa0513136 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0472232 | Endometrium | EEC | Neurotrophin signaling pathway | 30/1237 | 119/8465 | 1.54e-03 | 9.55e-03 | 7.12e-03 | 30 |
hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RIPK2 | SNV | Missense_Mutation | c.510N>T | p.Trp170Cys | p.W170C | O43353 | protein_coding | tolerated(0.13) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
RIPK2 | SNV | Missense_Mutation | c.206T>A | p.Ile69Asn | p.I69N | O43353 | protein_coding | deleterious(0.02) | probably_damaging(0.983) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
RIPK2 | SNV | Missense_Mutation | c.1336N>C | p.Asp446His | p.D446H | O43353 | protein_coding | deleterious(0) | possibly_damaging(0.721) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RIPK2 | insertion | Frame_Shift_Ins | novel | c.1618_1619insAACATAGTTTTTCTTCAGTTGTTCATTTCTTC | p.Met540LysfsTer14 | p.M540Kfs*14 | O43353 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
RIPK2 | SNV | Missense_Mutation | c.1218N>A | p.Phe406Leu | p.F406L | O43353 | protein_coding | tolerated(0.78) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RIPK2 | SNV | Missense_Mutation | c.218C>A | p.Ala73Asp | p.A73D | O43353 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
RIPK2 | SNV | Missense_Mutation | novel | c.570N>G | p.Ile190Met | p.I190M | O43353 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RIPK2 | SNV | Missense_Mutation | c.821C>T | p.Ala274Val | p.A274V | O43353 | protein_coding | tolerated(0.09) | probably_damaging(0.91) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RIPK2 | SNV | Missense_Mutation | rs775421386 | c.1600N>G | p.Leu534Val | p.L534V | O43353 | protein_coding | tolerated_low_confidence(0.05) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RIPK2 | SNV | Missense_Mutation | c.422C>A | p.Pro141His | p.P141H | O43353 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 315661219 | ||
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | PD-169316 | PD-169316 | 18408713 | |
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 384403681 | ||
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102513 | PONATINIB | |
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 385612179 | ||
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 381118799 | ||
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | SB-202190 | SB-202190 | 22951114 | |
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102664 | ||
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 348353647 | ||
8767 | RIPK2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 385612168 |
Page: 1 |